SEC Contract Filing

Filing Date: 2016-10-27

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>sgmo-ex101_156.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
sgmo-ex101_156.htm
</title>
</head>
<!-- NG Converter v4.0.5.2 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the &#8220;Commission&#8221;).&nbsp;&nbsp;Such portions have been redacted and are marked with a &#8220;[***]&#8221; in the place of the redacted language.&nbsp;&nbsp;The redacted information has been filed separately with the Commission.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EIGHTH AMENDMENT TO THE RESEARCH AND COMMERCIAL </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LICENSE OPTION AGREEMENT</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Parties to the Research and Commercial License Option Agreement of October 1, 2005 as previously amended (&#8220;Agreement&#8221;).&nbsp;&nbsp;Sangamo BioSciences, Inc., a Delaware corporation having its principal place of business at Point Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, CA 94804 (&#8220;Sangamo&#8221;), and Dow AgroSciences LLC, a Delaware limited liability company having its principal place of business at 9330 Zionsville Road, Indianapolis, IN 46268 (&#8220;DAS&#8221;), hereby further amend the Agreement as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.67%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Replace Section 1.63 with the following language:</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:11.33%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8220;1.63 &#8220;Stacking Crop Product&#8221;<font style="font-weight:normal;"> means a Crop Product that: </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:11.33%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) is a DAS Product, </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:11.33%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) is the direct result of using one or more ZFP Products to: </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:11.33%;text-indent:5.67%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) insert one or more DNA sequences from a different source into a plant, plant cell, or plant cell culture (in each case, whether constituting or derived from a vascular or non-vascular plant) wherein each such insertion causes a Trait that (A) is entirely due to expression of the protein encoded by such inserted DNA sequence (which DNA sequence has not been directly or indirectly modified through the use of a ZFP Product) and (B) is not due, in whole or in part, to (1) the modified expression of any pre-existing gene in such plant, plant cell or plant cell culture or (2) the modification or deletion of any coding or regulatory sequence of any pre-existing gene in such plant, plant cell or plant cell culture, or</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:11.33%;text-indent:5.67%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) deletes one or more existing DNA sequences in such plant, plant cell or plant cell culture that are not coding or regulatory sequences and do not have any known function, wherein such deletion(s) do not, separately or in combination, cause a Trait or modify the expression or coding sequence of any existing gene in such plant, plant cell or plant cell culture, and </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.67%;text-indent:5.67%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) is not the result of any other activity in the Field.&#8221;</p>
<div align=